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AbstrACt 
Objectives Indicators of guideline adherence are 
frequently used to examine the appropriateness of 
healthcare services. Only some potential indicators are 
actually usable for research with routine administrative 
claims data, potentially leading to a biased selection 
of research questions. This study aimed at developing 
a systematic approach to extract potential indicators 
from clinical practice guidelines (CPG), evaluate their 
feasibility for research with claims data and assess how 
the extracted set reflected different types of healthcare 
services. Diabetes mellitus (DM), Swiss national guidelines 
and health insurance claims data were analysed as a 
model case.
Methods CPG for diabetes patients were retrieved from 
the Swiss Endocrinology and Diabetes Society website. 
Recommendation statements involving a specific 
healthcare intervention for a defined patient population 
were translated into indicators of guideline adherence. 
Indicators were classified according to disease stage and 
healthcare service type. We assessed for all indicators 
whether they could be analysed with Swiss mandatory 
health insurance administrative claims data.
results A total of 93 indicators were derived from 15 
CPG, representing all sectors of diabetes care. For 63 
indicators, the target population could not be identified 
using claims data only. For 67 indicators, the intervention 
could not be identified. Nine (10%) of all indicators were 
feasible for research with claims data (three addressed 
gestational diabetes and screening, five screening for 
complications and one glucose measurement). Some types 
of healthcare services, eg, management of risk factors, 
treatment of the disease and secondary prevention, lacked 
corresponding indicators feasible for research.
Conclusions Our systematic approach could identify 
a number of indicators of healthcare service utilisation, 
feasible for DM research with Swiss claims data. Some 
areas of healthcare were covered less well. The approach 
could be applied to other diseases and countries, helping 
to identify the potential bias in the selection of indicators 
and optimise research.
IntrOduCtIOn 
Health insurance claims data are often used 
to evaluate the appropriateness and intensity 
of healthcare service utilisation in a country, 
region or hospital.1 2 The Dartmouth Atlas 
of Health Care in the USA3 is an example of 
such a healthcare service utilisation intensity 
map. Recently, a similar project, ‘Versorgungs-
atlas’, was launched in Switzerland.4 Health-
care service appropriateness may additionally 
be assessed with reference to the clinical 
indication for the service of interest. In this 
case, both the patient population with a clin-
ical indication and the corresponding service 
need to be identifiable. Claims data are used 
for this purpose in a variety of clinical areas 
as a valid substitute for clinical data.5–8 The 
resulting indicators, proportions of patients 
receiving the indicated healthcare services, 
can be regarded as clinical process quality 
indicators.9 They can be used for research as 
well as policy development—for example, to 
assess regional access to services or implemen-
tation of clinical practice guidelines (CPG).
The indicators are commonly extracted 
from CPG or Choosing Wisely lists.10 11 Indi-
cators of healthcare services overuse have 
been explored particularly frequently.12–14 
However, the selection and development 
of the indicators are often non-systematic.15 
strengths and limitations of this study
 ► This is the first study to explore the limited informa-
tion from claims data as a source of potential bias 
when selecting indicators for guideline adherence 
research.
 ► A systematic approach was used to develop a com-
prehensive set of adherence indicators from guide-
lines, that were then tested for feasibility with claims 
data.
 ► Only one clinical area (diabetes mellitus) in a specif-
ic country (Switzerland) was investigated as a model 
case, but the approach could be transferred to other 
areas of interest.
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Even when based on CPG and guided by clinical rele-
vance, the selection of the analysed indicators is at the 
discretion of the researchers and may be strongly influ-
enced by the availability of data.10 Feasibility is frequently 
used as a criterion to select healthcare quality indicators.16 
As a result, there may be a danger that some healthcare 
services research and monitoring could be driven by 
opportunities and data available rather than by a system-
atic assessment of relevant research questions from a 
patient or societal perspective.
Specifically, potential bias in indicator selection may 
arise as claims data typically do not cover all aspects of 
healthcare. In fee-for-service and bundled payment 
healthcare reimbursement systems, clinical information 
is normally not recorded with the reimbursement claim.17 
For example, in Swiss claims databases, outpatient diag-
noses and indications are not recorded with the provided 
outpatient services.18 With limited clinical information, 
some patient populations may not be accurately iden-
tifiable, and consequently, appropriateness of health-
care service utilisation in these populations may not be 
assessed. This could lead to a bias of disproportionate 
application of more easily assessable indicators.
Systematic development and application of indica-
tors of guideline adherence may reduce the possibility 
of imbalanced selection of topics in healthcare service 
utilisation research. A few recent studies have systemati-
cally extracted indicators of low-value care and evaluated 
their feasibility for research in primary care19 or inpatient 
settings.11 In contrast to extracting only the feasible indi-
cators, the aim of this study was to additionally quantify 
the indicators unavailable and healthcare services not 
reflected due to limitations of claims data. Our study 
aimed to develop a comprehensive, systematic approach 
to extract and assess guideline adherence indicators for 
a case model of diabetes mellitus (DM) in Switzerland. 
CPG were used to systematically develop indicators and 
mandatory health insurance data to test their feasibility for 
research. DM is an example of a highly prevalent chronic 
disease that has a comprehensive national guideline set 
in Switzerland, published by the Swiss Society for Endo-
crinology and Diabetes (Schweizerischen Gesellschaft 
für Endokrinologie und Diabetologie).20 Research on 
specific DM services indicators based on claims data has 
already been shown to be feasible.21 22 However, the scope 
of all feasible indicators has not been assessed systemati-
cally in diabetes or any other single clinical area across all 
healthcare settings.
MethOds
systematic development of guideline adherence indicators
In the first step, we designed a systematic approach for 
the development of guideline adherence indicators for 
a specific patient population or clinical area. As we have 
found no previous published detailed approach, we 
designed the algorithm based on the agreement of all 
study authors. The final approach is illustrated in figure 1.
Second, we applied this approach to DM and Swiss 
administrative claims data. We retrieved all current 
guideline and recommendation documents published 
online on the official website of the Swiss Endocrinology 
and Diabetes Society in German.20 From the documents 
retrieved, DM-CPG were identified, resulting in 15 unique 
documents.
An indicator of guideline adherence was defined as the 
ratio of patients who actually receive a healthcare service, 
to all patients with an indication for that specific service. 
Therefore, to translate a recommendation statement to 
an indicator, both the patient population with the indi-
cation for a service and the patients receiving the service 
need to be defined. We selected recommendation state-
ments that had both the indication (population) and 
healthcare service defined. Exclusion criteria for recom-
mendation statements were as follows:
1. The recommendation does not result in any interven-
tion directly affecting the individual patient (eg, a cer-
tain risk stratification tool recommended for a specific 
Figure 1 Systematic approach for identifying indicators of guideline adherence for research with claims data.
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patient population; documentation of healthcare ser-
vice delivery).
2. The recommendation expresses no preference for a 
specific service, in the presence of multiple options 
(eg, initial therapy for DM patients with symptomatic 
hyperglycaemia or metabolic decompensation should 
be started with insulin with or without metformin).
3. The recommendation is a non-specific principle (eg, 
pharmaceutical therapy should be started without un-
necessary delay).
4. No recommendation signalling words (such as 
should [‘soll’, ‘sollte’], must [‘muss’], we recommend [‘wir 
empfehlen’], is not recommended [‘ist nicht empfohlen’] 
and so on) are used in the recommendation (eg, gen-
eral statements of common current practice).
In order to maintain a comprehensive approach, we 
did not further exclude recommendation statements 
based on the nature of the recommended intervention 
(eg, interventions of general vs specialised practice, posi-
tive vs negative recommendations, recommendations for 
diabetes management vs comorbidities management in 
diabetic patients).
Eligible recommendation statements were then trans-
lated into indicators of guideline adherence. We clas-
sified the indicators according to: (1) disease stage 
(screening—general population; risk factor—patients 
with an established risk factor for diabetes; disease—
patients with diabetes), (2) area of healthcare service 
(screening—testing of population without symptoms; 
diagnosis—interventions to confirm or reject the diag-
nosis; primary prevention—interventions to prevent the 
onset of disease; control—routine interventions for a 
patient with a disease; treatment—therapeutic measures; 
secondary prevention—interventions to prevent disease 
progression) and (3) intervention type (clinical test—a 
specific non-laboratory examination, such as blood pres-
sure measurement, medical history taking or a question-
naire administration; laboratory test—blood or urine 
laboratory analysis; consultation—a consultation of a 
specialist, such as ophthalmologist, a teaching session or 
a specific medical advice given during a physician consul-
tation; medication—direct pharmacological interven-
tion; device use—prescription of a medical device, such 
as for continuous glucose measurement). This classifica-
tion broadly covers all types, functions and modalities of 
healthcare services.9
screening indicators for feasibility
As a next step, information from administrative manda-
tory health insurance claims data was identified and char-
acterised in cooperation with the research team of a major 
healthcare insurance provider in Switzerland (BB, CB, 
EB). The claims database consists of information on reim-
bursed healthcare diagnostic and therapeutic services, 
deemed appropriate clinically and cost-effective, from all 
healthcare service providers settings. The information is 
coded according to international or national classifica-
tion or tariff systems. Major types of patient information 
available in the claims database and the corresponding 
coding systems used are given in table 1. In addition, 
demographic data, such as sex and age, are available.
Next, it was checked if both the addressed population 
and intervention of the indicator could be identified in 
the claims data. Indicators were excluded as not feasible 
if either the patient population or intervention could 
not be identified. The reason for exclusion was noted. 
These steps were performed by two authors in duplicate 
(AU and CB), and instances of disagreement resolved by 
discussion with the other authors.
For example, one of the identified CPG in Switzerland, 
Criteria for Good Disease Management of Diabetes in 
Primary Care (Kriterien für ein „gutes “Disease Management 
Diabetes in der Grundversorgung), recommends that ‘to 
fulfil the score criteria, glycated haemoglobin (HbA1c) 
should be measured at least two times per year (for 
diabetes patients)”. The recommendation identifies 
both the population (diabetes patients) and the inter-
vention (HbA1c at least biannually), therefore the trans-
lated indicator is the fraction of all diabetes patients who 
get the test done at least biannually. According to our 
classification, this is an indicator of a laboratory control 
test performed routinely for diabetes patients. Eligibility 
of the indicator can now be checked, and the required 
variables identified in the claims database (to define the 
population: data on the prescription of diabetes medi-
cation; to define the intervention: HbA1c outpatient test 
performance).
Table 1 Major categories of patient data available in Swiss 
mandatory health insurance claims databases
Data category Inpatient data
Outpatient 
data
Diagnosis SwissDRG, ICD-
10-GM
– 
Procedures SwissDRG, CHOP Tarmed
Laboratory tests – Analysenliste
Medication – ATC
Materials and devices – MiGeL
Summary of services SwissDRG – 
Abbreviations of data sources: SwissDRG (Swiss Diagnosis-
Related Groups, a classification of inpatient cases, based on 
diagnoses, procedures and other clinical information), CHOP 
(Schweizerische Operationsklassifikation, a classification of 
inpatient procedures), ICD-10-GM (International Classification of 
Diseases, 10th revision, German Modification, codes for primary 
and secondary diagnoses for each hospitalisation episode of 
an inpatient), Tarmed (classification of outpatient procedures 
and services), Analysenliste (outpatient laboratory test codes), 
ATC (Anatomical Therapeutic Chemical Classification System, 
code and quantity of a prescription drug), MiGeL (Mittel und 
Gegenständeliste, classification of therapeutic materials and 
devices).
References for the listed data sources are provided in online 
supplementary file 1.
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Patient and public involvement
This study was performed as part of the National Research 
Programme 74 ‘Smarter Health Care’ of the Swiss National 
Science Foundation. Patients and public, including policy 
makers and healthcare services providers, are involved in 
interpreting, disseminating and translating the overall 
results of studies conducted under this programme. 
Patients were not directly involved in the planning and 
conducting of this study.
results
From 15 CPG on DM, 93 explicit recommendation state-
ments were translated into indicators (figure 2). Nine 
(10%) of these indicators could be identified from the 
administrative claims data available (ie, both the popula-
tion and the indicated intervention could be identified) 
and would be principally feasible for further analysis 
(table 2). Specific codes to identify the patient popula-
tion and the intervention for each feasible indicator from 
the claims data sources are provided in online supple-
mentary file 2.
For 63 indicators, the patient population could not be 
identified, and for 67 indicators, the intervention could 
not be identified with sufficient accuracy (figure 2). 
Missing clinical information (eg, clinical examination 
details) prevented the identification of 45 populations 
and 26 interventions. Missing test results (eg, HbA1c 
test value) resulted in a failure to identify another 17 
Figure 2 Selection of clinical practice guidelines, recommendation statements and indicators of guideline adherence.
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populations. In other cases, populations and interven-
tions could not be identified due to unavailable initial 
date of a diagnosis or a prescription, information on the 
utilisation frequency of diagnostic tests or devices (except 
when monthly utilisation rate could be used as a proxy 
for daily utilisation), and limited information on the use 
of some devices.
Of the indicators suitable for analysis with claims data, 
three addressed gestational diabetes and DM screening, 
five addressed routine screening for DM complica-
tions and one the mode of blood glucose measurement 
(table 2). Indicators suitable for analysis were distrib-
uted unequally across disease stages, areas of healthcare 
services and interventions (table 3). For some areas of 
healthcare services, no feasible indicators were available. 
Examples include interventions to diagnose and treat risk 
factors, medication and device use for disease treatment, 
and secondary prevention of complications.
dIsCussIOn
We developed a systematic approach and identified 
potential indicators of guideline adherence that can 
be used for research with Swiss health insurance claims 
data, using DM as a case model. Only a fraction of 
indicators generated from CPG recommendation state-
ments was feasible for research, distributed unequally 
across different healthcare services types and areas.
Claims databases are a frequent source of data for 
research on healthcare utilisation,1 increasingly used in 
Switzerland.18 21 23–26 Limitations of the claims data could 
lead to some of the potential indicators being over- or 
under-represented in research with this data source. Ulti-
mately, such a selective set of indicators, when used to 
link healthcare funding to provider performance, could 
potentially distort the way healthcare is provided. In our 
study, no identified indicator was feasible to assess medi-
cation or continuous glucose monitoring device use, even 
though these service categories comprised the largest 
number of potential indicators (table 3). In contrast, all 
four identified indicators of control laboratory testing 
were feasible for research. Such imbalanced distribution 
confirms a risk of bias, if the indicator selection is guided 
by the available data rather than the clinical or public 
health relevance.
Despite potential shortcomings, research on health-
care service utilisation with claims data is attractive as 
they provide real-life, up-to-date information and may be 
a valid substitute for clinical data in some cases.5 They 
Table 2 Feasible indicators based on diabetes recommendation statements
Reference clinical practice 
guideline Population
Data 
source Intervention
Data 
source
Primary Health Care Good 
Disease Management 
Criteria*
1 DM patients ATC HbA1c test twice yearly Ana
2 DM patients under 75 years ATC Low density lipoprotein (LDL) 
cholesterol test annually
Ana
3 DM patients ATC Serum creatinine and 
microalbuminuria tests annually
Ana
4 DM patients ATC Ophthalmologist consultation 
annually
TM
Gestational Diabetes 
Screening†
5/6‡ Pregnant women in 
24–28 weeks / in the third 
trimester of pregnancy, if 
not screened earlier
DRG, Ana Oral glucose tolerance test 
(OGTT) or fasting glucose test
Ana
7 Patients with recent history 
of gestational diabetes
ICD, DRG DM screening 4–8 weeks after 
delivery
Ana
Recommendations 
Concerning Insulin Therapy 
for Care-dependent Patients§
8 DM patients dependent on 
care and insulin therapy
ATC, TM HbA1c four times and 
creatinine, serum electrolytes 
tests 1–2 times yearly
Ana
Blood Glucose Self-
Monitoring¶
9 DM patients on intensive 
insulin therapy
ATC 7–8 blood glucose 
measurements daily
MiGeL
URL links to the referenced guidelines are provided in online supplementary file 3.
*DE: Kriterien für ein ‘gutes’ Disease Management Diabetes in der Grundversorgung.
†DE: Screening des Gestationsdiabetes.
‡Two recommendation statements are combined for this indicator.
§DE: Empfehlungen bezüglich der Insulintherapie bei unselbständigen Patienten;
¶DE: Selbst-Monitoring der Blutglukose.
Ana, Analyseliste (outpatient laboratory test codes); ATC, Anatomical Therapeutic Chemical Classification System; DM, diabetes mellitus; 
DRG, diagnosis-related group; HbA1c, glycated haemoglobin; ICD, International Statistical Classification of Diseases and Related Health 
Problems, 10th revision; MiGeL, Mittel und Gegenständeliste (classification of therapeutic materials and devices); TM, TARMED Tarif 
(classification of outpatient procedures and services).
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are gathered from all settings and providers and are 
recorded in standard variables (table 1). Therefore, they 
are easily comparable across patients and providers and 
can be used to construct country-wide healthcare utilisa-
tion intensity maps.3 4 Longitudinal data can be linked 
directly to the patient, as implemented in Sweden,27 
leading to a unified national database. In Switzerland, the 
clinical details are currently stored locally by the service 
provider, and the administrative information is linked to 
the patient through the insurer, with a strategy to imple-
ment a unified eHealth record database in a few years.28
The number of feasible indicators could be increased by 
allowing more uncertainty in the population or interven-
tion definitions. For example, DM type is not recorded in 
the claims database. However, it could be estimated from 
patient characteristics and prescription patterns.29 Indi-
cators requiring knowledge of DM type could be consid-
ered on this basis. Further sensitivity analyses for patients 
hospitalised in the years of interest could be based on 
inpatient diagnoses, which are recorded in the claims 
data. However, complex identification algorithms might 
decrease the sensitivity or specificity of the indicators, 
and render the retrieval and analysis of the data overly 
complicated.
In addition to reimbursement claims, other data 
sources could be explored for systematic application of 
guidelines adherence indicators. Electronic healthcare 
record data, gathered on a national level, could provide 
more clinical details. This could extend the spectrum 
of the feasible indicators, as major reasons for indicator 
exclusion in this study were missing clinical examina-
tion and laboratory test results. However, health records 
might face other problems—such as different interpre-
tation across providers, missing data and various quality 
issues. Another alternative data source is disease regis-
tries, providing focused information on guideline adher-
ence in specific diseases, such as myocardial infarction.30
Although the general approach developed in our study 
is broadly applicable, the model case of diabetes care in 
Switzerland is limited to the specificities of the national 
claims data structure and the peculiarities of the anal-
ysed disease. Data collected in claims databases vary by 
country,1 31 limiting the possibility to apply the developed 
indicators internationally. Most of the reported indicators 
of healthcare service utilisation have been developed in 
the USA,12 where unlike in Switzerland outpatient diag-
noses in Medicare claims data may be available.32 DM 
patients in Swiss claims data could be identified by drug 
prescription; however, DM controlled by diet only would 
be missed.33 Some of the indicators developed in this 
study would rely on indirect identification, for example, 
the stage of pregnancy would have to be estimated from 
the date of delivery. All indicators, especially relying 
on indirect identification algorithms, should ideally be 
assessed with sensitivity analysis and validated. Algorithms 
to identify specific patient populations with claims data 
are frequently validated; however, validation is rarely 
applied to indicators of utilisation.34 35
DM is an example of a disease for which the medications 
prescribed are specific enough to suffice for patient iden-
tification. Only a limited range of other diseases can be 
identified in a similarly clear-cut way (eg, hypothyroidism, 
osteoporosis or tuberculosis). For many frequently 
prescribed drugs, the indications are wide and overlap-
ping, precluding identification of a specific disease or at 
least rendering it more uncertain.36 This limits the trans-
ferability of our approach to some diseases, although 
algorithms also considering non-drug outpatient services 
can provide solutions in some cases (eg, combining a 
prescription of a drug at a specific dosage by a certain 
specialty physician). We ensured a systematic approach 
by pre-specifying the inclusion and exclusion criteria 
for indicators, and with a concurrent assessment by two 
authors. However, a further limitation is related to the 
structure of the CPG used for indicator extraction. Inac-
curacies may have arisen due to inherent uncertainties in 
the formulations of the recommendation statements in 
Table 3 Potential and feasible indicators of guideline 
adherence for diabetes mellitus patients
Disease 
stage
Area of 
healthcare 
service
Intervention 
type
No. of 
indicators
No. of 
feasible 
indicators
93 9 (10%)
Screening Screening Clinical test 1 0
Laboratory 
test
2 2
Risk factor Screening Laboratory 
test
1 0
Diagnosis Laboratory 
test
4 0
Primary 
prevention
Consultation 1 0
Disease Screening Clinical test 1 0
Diagnosis Laboratory 
test
1 1
Device use 1 0
Control Consultation 3 1
Clinical test 4 0
Laboratory 
test
4 4
Treatment Clinical test 3 0
Laboratory 
test
12 1
Consultation 6 0
Medication 19 0
Device use 25 0
Secondary 
prevention
Consultation 3 0
Medication 2 0
The categories used for the classification of disease stages, 
areas of healthcare services and intervention types are 
explained in the methods section.
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these CPG. Recommendation statements were usually not 
specifically highlighted in the analysed CPG texts and did 
not have standard formatting or wording, which could 
lead to a slightly different interpretation by different 
reviewers. The strength of recommendations or the level 
of evidence were rarely stated in the analysed guidelines, 
which would have been useful criteria to classify the indi-
cators. One of the reasons for these shortcomings is that 
CPG are not specifically designed for indicator construc-
tion (just as claims databases are not designed for their 
assessment). These shortcomings could be minimised by 
analysing guidelines with clearly structured recommenda-
tion statements, such as in the Consensus Report by the 
American Diabetes Association and the European Associ-
ation for the Study of Diabetes.37
Some of the feasible DM indicators identified in this 
study have already been demonstrated to be fruitful for 
research. Huber et al21 used medication prescriptions to 
identify a population of drug-treated diabetes patients 
from the claims database. The investigated interventions 
were the frequency of HbA1c, lipid profile and nephrop-
athy status testing and ophthalmologist visits. These indi-
cators were identified as feasible in this study as well.
COnClusIOns
Using the systematic approach, a number of indicators 
could be identified for research on diabetes healthcare 
service utilisation with claims data. Not all healthcare 
services were represented equally. We believe that our 
approach could be applied to other diseases and databases 
in other countries, helping to identify the potential bias 
in the selection of indicators and optimise such research. 
In parallel, the structure and content of claims databases 
may be optimised to allow more efficient healthcare 
services research in the future. More clearly, structured 
guidelines with evident recommendation statements 
would also facilitate their extraction. Comparing the 
validity of indicators constructed for different national 
databases could further inform policymakers regarding 
the advantages of different data collection strategies.
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